Open-Label CDCA 250 mg TID for Cerebral Thrombosis Xanthomatosis

Phase-Based Progress Estimates
Cerebral Thrombosis XanthomatosisOpen-Label CDCA 250 mg TID - Drug
Any Age
All Sexes
What conditions do you have?

Study Summary

This trial tests the effectiveness of an experimental drug for treating migraines in adults and children.

Eligible Conditions
  • Cerebral Thrombosis Xanthomatosis

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Week 4 and Week 16

Week 16
Change in Bile Alcohols.
Change in Urinary Bile Alcohols

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Adult Cohort
1 of 2
Pediatric Cohort
1 of 2

Experimental Treatment

12 Total Participants · 2 Treatment Groups

Primary Treatment: Open-Label CDCA 250 mg TID · Has Placebo Group · Phase 3

Adult CohortExperimental Group · 4 Interventions: Placebo, Rescue Medication CDCA 250 mg TID, Open-Label CDCA 250 mg TID, Blinded CDCA 250 mg TID · Intervention Types: Drug, Drug, Drug, Drug
Pediatric Cohort
Experimental Group · 1 Intervention: CDCA Weight-Based Dose TID · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 3

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: week 4 and week 16

Who is running the clinical trial?

Travere Therapeutics, Inc.Lead Sponsor
18 Previous Clinical Trials
177,299 Total Patients Enrolled

Eligibility Criteria

Age Any Age · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: